Our approved brands remain a key driver of performance, while expanded international partnerships and steady advancement in our clinical development programs further strengthen our position. We are also evaluating select acquisition opportunities that align with our strategic objectives. As we look ahead, we remain committed to executing our growth strategy and delivering long-term value.

We recently reported strong progress on several key fronts:

• In February 2025, we announced positive top-line Phase II results from our ifetroban study in Duchenne muscular dystrophy (DMD) . This milestone was shared during a late-breaking presentation at the Muscular Dystrophy Association’s annual conference in March and marks a major validation of our development platform.

• Vibativ®, our potent antibiotic, received regulatory approval in China, opening the door to the world’s second-largest pharmaceutical market. We anticipate the product will launch there later this year.

• We posted strong first-quarter results, with $11.7 million in revenue — a 38% increase year-over-year, and significant growth in earnings and cashflow from operations.

We’re also making progress at Cumberland Emerging Technologies (CET), where we continue to operate the Nashville Life Sciences Center and are advancing a new diagnostic product for gastrointestinal bleeding.

2025 is shaping up to be another pivotal year for Cumberland. With continued growth, international expansion and clinical milestones ahead, we remain focused on delivering value and fulfilling our mission: working together to provide unique products that improve the quality of patient care.